insights_archives

In global drug development, companies often focus heavily on protocol design, regulatory strategy, and operational feasibility before entering Japan. However, one of the most important determinants of long-term success is frequently underestimated: early alignment with Key Opinion Leaders (KOLs). Many

Insufficient Early Alignment with Japanese Clinical Expectations One of the most common causes of delay is the assumption that global clinical development programs will automatically satisfy Japanese regulatory expectations. Although Japan has become increasingly globalized in drug development, PMDA still

1. Executive Summary Japan represents one of the most attractive yet complex pharmaceutical markets globally. As the third-largest pharmaceutical market, it offers strong reimbursement systems, a well-structured healthcare infrastructure, and significant demand driven by an aging population. However, successful market

Strategic Approaches for Overseas Biotech and Pharmaceutical Companies Entering Japan 1. Executive Summary Key Opinion Leaders (KOLs) play a critical role in pharmaceutical and biotech strategy, particularly in Japan where clinical practice patterns, academic influence, and guideline development are tightly

1. Approval-Centric Thinking – Case: Biotech for a rare disease drug Case: A rare disease drug (analogous to Ultragenyx-type assets) received PMDA approval.Expected price (global benchmark): JPY 120M/yearActual NHI price: JPY 70M/year (~-40%)Sales forecast: JPY 10B → Actual: JPY 5–6BRoot

In global drug development, companies often focus heavily on protocol design, regulatory strategy, and operational feasibility before entering Japan. However, one of the most important determinants of long-term success is frequently underestimated: early alignment with Key Opinion Leaders (KOLs). Many